Showing results (371-380 of 470) with videos related to
Sort By:
Pageof 47
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedulesRanjana H Advani, Herbert I Hurwitz, Michael S Gordon, et al.Blood|November 3, 2011
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 studyYoun H Kim, Dita Gratzinger, Cameron Harrison, et al.Blood|September 6, 2012
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialKing L Tan, David W Scott, Fangxin Hong, et al.British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology|May 5, 2017
Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade)Dinesh Chandra Doval, Dinesh Bhurani, Reena Nair, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)Lynne I Wagner, Fengmin Zhao, Fangxin Hong, et al.Blood|September 29, 2020
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphomaPamela B Allen, Hatice Savas, Andrew M Evens, et al.British Journal of Haematology|January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab eraPeter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.South Asian Journal of Cancer|March 24, 2025
Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC)Purvish M Parikh, Amish Vora, Rajan Yadav, et al.Pageof 47